ETF
Data as on 30-10-2026
Mirae Asset Nifty 500 Healthcare ETF is a mutual fund run by Mirae Asset Mutual Fund. On 30-09-2026, it managed ₹15 Cr of investors' money.
NAV on 30-10-2026: ₹21.44 (up 1.37% that day).
Returns as on 30-10-2026. Up to one year they are absolute returns. Longer periods are a rate per year.
| Period | 1M | 3M | 6M | 1Y | 3Y | 5Y | 10Y |
|---|---|---|---|---|---|---|---|
| This fund | +1.43% | −0.66% | +12.95% | -- | -- | -- | -- |
| Nifty500 Healthcare TRI | +1.44% | −0.62% | +13.06% | +12.42% | -- | -- | -- |
| Category average | -- | -- | -- | -- | -- | -- | -- |
| Best in category | -- | -- | -- | -- | -- | -- | -- |
| Worst in category | -- | -- | -- | -- | -- | -- | -- |
| Rank in category | -- | -- | -- | -- | -- | -- | -- |
No category comparison is shown: this fund's category is too broad to compare, or has fewer than five funds.
What each plan charges a year, in force from 29-09-2026
| Plan | Base expense ratio | Brokerage | Transaction costs | Levies and GST | Total expense ratio |
|---|---|---|---|---|---|
| Fund | -- | 0.00% | 0.00% | 0.00% | 0.35% |
The expense ratio comes out of the fund's assets every day, so every return on this page is already after it. Base expense ratio: the fund house's own fee. The total adds brokerage, the cost of executing trades, and statutory levies with GST. From AMFI's expense ratio file.
Asset allocation as on 30-09-2026
100.0%Equity
| Asset | Fund |
|---|---|
| Equity | 100.0% |
| Market cap | Fund |
|---|---|
| Large Cap | 36.0% |
| Mid Cap | 45.6% |
| Small Cap | 18.3% |
Share of the whole fund. Groups follow AMFI's latest list, as SEBI defines them: Large Cap is the 100 largest companies, Mid Cap the next 150, Small Cap the rest.
Sector allocation of the fund's stocks as on 30-09-2026
Pharmaceuticals & Biotechnology77.8%
Healthcare Services21.7%
Healthcare Equipment & Supplies0.5%
| Sector | July 2026 | August 2026 | September 2026 | Change |
|---|---|---|---|---|
| Pharmaceuticals & Biotechnology | 75.4% | 76.4% | 77.8% | +2.4% |
| Healthcare Services | 23.9% | 23.1% | 21.7% | −2.2% |
| Healthcare Equipment & Supplies | 0.5% | 0.5% | 0.5% | 0.0% |
Each sector's share of the fund at the end of each month. The five largest sectors of September 2026. Change: from July 2026 to September 2026, in % of the fund.
As on 30-09-2026 · 44 holdings · from the fund house's monthly portfolio
| Holdings | Sector | Weight% | Holdings trend | 1M change |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | Pharmaceuticals & Biotechnology | 10.13% | +13.9% | |
| Divi's Laboratories Ltd. | Pharmaceuticals & Biotechnology | 8.76% | +6.5% | |
| Apollo Hospitals Enterprise Ltd. | Healthcare Services | 6.24% | +6.5% | |
| Laurus Labs Ltd. | Pharmaceuticals & Biotechnology | 5.72% | +6.6% | |
| Cipla Ltd. | Pharmaceuticals & Biotechnology | 5.62% | +6.5% | |
| Dr. Reddy's Laboratories Ltd. | Pharmaceuticals & Biotechnology | 5.58% | +6.6% | |
| Torrent Pharmaceuticals Ltd. | Pharmaceuticals & Biotechnology | 5.24% | +6.9% | |
| Max Healthcare Institute Ltd. | Healthcare Services | 5.13% | +6.5% | |
| Lupin Ltd. | Pharmaceuticals & Biotechnology | 3.66% | +6.5% | |
| Aurobindo Pharma Ltd. | Pharmaceuticals & Biotechnology | 3.43% | +6.3% | |
| Fortis Healthcare Ltd. | Healthcare Services | 2.98% | +6.5% | |
| Glenmark Pharmaceuticals Ltd. | Pharmaceuticals & Biotechnology | 2.61% | +6.6% | |
| Alkem Laboratories Ltd. | Pharmaceuticals & Biotechnology | 2.31% | +9.9% | |
| Zydus Lifesciences Ltd. | Pharmaceuticals & Biotechnology | 2.14% | +5.5% | |
| Mankind Pharma Ltd. | Pharmaceuticals & Biotechnology | 2.10% | +6.7% | |
| IPCA Laboratories Ltd. | Pharmaceuticals & Biotechnology | 1.98% | +6.5% | |
| Biocon Ltd. | Pharmaceuticals & Biotechnology | 1.91% | +4.0% | |
| Gland Pharma Ltd. | Pharmaceuticals & Biotechnology | 1.71% | +6.6% | |
| Sai Life Sciences Ltd. | Pharmaceuticals & Biotechnology | 1.56% | +6.8% | |
| Krishna Institute of Medical Sciences Ltd. | Healthcare Services | 1.48% | +9.7% | |
| Aster DM Quality Care Ltd. | Healthcare Services | 1.38% | +6.5% | |
| Neuland Laboratories Ltd. | Pharmaceuticals & Biotechnology | 1.36% | +6.5% | |
| Wockhardt Ltd. | Pharmaceuticals & Biotechnology | 1.30% | +6.6% | |
| Acutaas Chemicals Ltd. | Pharmaceuticals & Biotechnology | 1.26% | +6.7% | |
| Ajanta Pharma Ltd. | Pharmaceuticals & Biotechnology | 1.22% | +15.1% | |
| Dr. Lal Path labs Ltd. | Healthcare Services | 1.15% | +6.7% | |
| Abbott India Ltd. | Pharmaceuticals & Biotechnology | 1.04% | +7.3% | |
| Piramal Pharma Ltd. | Pharmaceuticals & Biotechnology | 0.95% | +6.4% | |
| Granules India Ltd. | Pharmaceuticals & Biotechnology | 0.93% | +8.3% | |
| Narayana Hrudayalaya Ltd. | Healthcare Services | 0.92% | +6.5% | |
| Global Health Ltd. | Healthcare Services | 0.90% | +10.3% | |
| Onesource Specialty Pharma Ltd. | Pharmaceuticals & Biotechnology | 0.89% | +6.5% | |
| Glaxosmithkline Pharmaceuticals Ltd. | Pharmaceuticals & Biotechnology | 0.85% | +6.6% | |
| Anthem Biosciences Ltd. | Pharmaceuticals & Biotechnology | 0.69% | +29.1% | |
| Emcure Pharmaceuticals Ltd. | Pharmaceuticals & Biotechnology | 0.60% | +29.7% | |
| Natco Pharma Ltd. | Pharmaceuticals & Biotechnology | 0.55% | +6.7% | |
| Cohance Lifesciences Ltd. | Pharmaceuticals & Biotechnology | 0.54% | +6.5% | |
| Vijaya Diagnostic Centre Ltd. | Healthcare Services | 0.52% | +6.5% | |
| Syngene International Ltd. | Healthcare Services | 0.51% | +6.4% | |
| Rainbow Children's Medicare Ltd. | Healthcare Services | 0.49% | +6.4% | |
| Polymedicure Ltd. | Healthcare Equipment & Supplies | 0.47% | +6.4% | |
| Rubicon Research Ltd. | Pharmaceuticals & Biotechnology | 0.43% | New | |
| Caplin Point Laboratories Ltd. | Pharmaceuticals & Biotechnology | 0.40% | +7.0% | |
| Concord Biotech Ltd. | Pharmaceuticals & Biotechnology | 0.34% | +5.9% |
All changes are between August 2026 and September 2026
| Sun Pharmaceutical Industries Ltd. | Added | +13.9% | 10.13% |
|---|---|---|---|
| Divi's Laboratories Ltd. | Added | +6.5% | 8.76% |
| Apollo Hospitals Enterprise Ltd. | Added | +6.5% | 6.24% |
| Laurus Labs Ltd. | Added | +6.6% | 5.72% |
| Cipla Ltd. | Added | +6.5% | 5.62% |
| Dr. Reddy's Laboratories Ltd. | Added | +6.6% | 5.58% |
| Max Healthcare Institute Ltd. | Added | +6.5% | 5.13% |
| Torrent Pharmaceuticals Ltd. | Added | +6.9% | 5.24% |
| Lupin Ltd. | Added | +6.5% | 3.66% |
| Aurobindo Pharma Ltd. | Added | +6.3% | 3.43% |
| Fortis Healthcare Ltd. | Added | +6.5% | 2.98% |
| Glenmark Pharmaceuticals Ltd. | Added | +6.6% | 2.61% |
| Alkem Laboratories Ltd. | Added | +9.9% | 2.31% |
| Zydus Lifesciences Ltd. | Added | +5.5% | 2.14% |
| Mankind Pharma Ltd. | Added | +6.7% | 2.10% |
| Biocon Ltd. | Added | +4.0% | 1.91% |
| IPCA Laboratories Ltd. | Added | +6.5% | 1.98% |
| Gland Pharma Ltd. | Added | +6.6% | 1.71% |
| Sai Life Sciences Ltd. | Added | +6.8% | 1.56% |
| Krishna Institute of Medical Sciences Ltd. | Added | +9.7% | 1.48% |
| Aster DM Quality Care Ltd. | Added | +6.5% | 1.38% |
| Neuland Laboratories Ltd. | Added | +6.5% | 1.36% |
| Wockhardt Ltd. | Added | +6.6% | 1.30% |
| Acutaas Chemicals Ltd. | Added | +6.7% | 1.26% |
| Ajanta Pharma Ltd. | Added | +15.1% | 1.22% |
| Dr. Lal Path labs Ltd. | Added | +6.7% | 1.15% |
| Abbott India Ltd. | Added | +7.3% | 1.04% |
| Piramal Pharma Ltd. | Added | +6.4% | 0.95% |
| Narayana Hrudayalaya Ltd. | Added | +6.5% | 0.92% |
| Granules India Ltd. | Added | +8.3% | 0.93% |
| Global Health Ltd. | Added | +10.3% | 0.90% |
| Glaxosmithkline Pharmaceuticals Ltd. | Added | +6.6% | 0.85% |
| Onesource Specialty Pharma Ltd. | Added | +6.5% | 0.89% |
| Anthem Biosciences Ltd. | Added | +29.1% | 0.69% |
| Emcure Pharmaceuticals Ltd. | Added | +29.7% | 0.60% |
| Natco Pharma Ltd. | Added | +6.7% | 0.55% |
| Syngene International Ltd. | Added | +6.4% | 0.51% |
| Cohance Lifesciences Ltd. | Added | +6.5% | 0.54% |
| Vijaya Diagnostic Centre Ltd. | Added | +6.5% | 0.52% |
| Jubilant Pharmova Ltd. | Sold out | −100% | was 0.50% |
| Pfizer Ltd. | Sold out | −100% | was 0.50% |
| Rainbow Children's Medicare Ltd. | Added | +6.4% | 0.49% |
| Eris Lifesciences Ltd. | Sold out | −100% | was 0.50% |
| Polymedicure Ltd. | Added | +6.4% | 0.47% |
| Indegene Ltd. | Sold out | −100% | was 0.45% |
| Rubicon Research Ltd. | New | New | 0.43% |
| Caplin Point Laboratories Ltd. | Added | +7.0% | 0.40% |
| Concord Biotech Ltd. | Added | +5.9% | 0.34% |
| Blue Jet Healthcare Ltd. | Sold out | −100% | was 0.21% |
No stocks in this group for September 2026.
A change is counted by the number of shares the fund holds, not by price. A stock can become a smaller part of the fund in a month when the fund bought more of it, if its price fell. Debt papers are left out.
Funds with the most similar portfolios, across every fund house and category
| Fund | Overlap | Holdings in common | |
|---|---|---|---|
| Bandhan BSE Healthcare Index FundIndex · Bandhan | 85.9% | 44 | Compare |
| Motilal Oswal BSE Healthcare ETFETF · Motilal Oswal | 85.1% | 44 | Compare |
| DSP Nifty Healthcare ETFETF · DSP | 79.8% | 20 | Compare |
| DSP Nifty Healthcare Index FundIndex · DSP | 79.8% | 20 | Compare |
| Aditya Birla Sun Life Nifty Healthcare ETFETF · Aditya Birla Sun Life | 79.8% | 20 | Compare |
| Axis NIFTY Healthcare ETFETF · Axis | 79.8% | 20 | Compare |
| ICICI Prudential Nifty Healthcare ETFETF · ICICI Prudential | 79.8% | 20 | Compare |
| ITI Pharma and Healthcare FundThematic · ITI | 76.0% | 31 | Compare |
Overlap: for each holding both funds own, the smaller of its two weights, added up. 40% means 40% of each fund's money sits in positions the other also holds. From each fund's latest monthly portfolio, matched by ISIN. Cash and hedged positions are left out. Funds that overlap under 10% are not listed. A high overlap does not make two funds the same: their costs, lock-in and category can differ.
Fund facts from the scheme summary document, as on 16-10-2026
Rules in force from 23-07-2024 (Finance Act 2024). Tax depends on your own income; this is general information, not tax advice.
Mirae Asset Nifty 500 Healthcare ETF is a mutual fund from Mirae Asset Mutual Fund. Its category is ETF. Its benchmark is Nifty500 Healthcare TRI. At the end of September 2026 it held 44 securities.
Ekta Gala
Fund manager of Mirae Asset Nifty 500 Healthcare ETF
amp
Fund manager of Mirae Asset Nifty 500 Healthcare ETF
Ritesh Patel
Fund manager of Mirae Asset Nifty 500 Healthcare ETF
See all funds of Mirae Asset Mutual Fund
AUM moves with money invested or taken out, and with the value of what the fund holds.
Returns, risk, costs and the stocks they share, side by side
The NAV is ₹21.4418, as on 30-10-2026.
The fund charges 0.35% a year. This is the figure the fund house reported to AMFI, in force from 29-09-2026.
Mirae Asset Nifty 500 Healthcare ETF managed ₹15.36 Cr on 30-09-2026, as its fund house reported in its monthly portfolio.
At the end of September 2026 the largest holdings were SUNPHARMA (10.13%), DIVISLAB (8.76%), APOLLOHOSP (6.24%), LAURUSLABS (5.72%), CIPLA (5.62%). The fund held 44 securities in all.
It bought 1 new stock: Rubicon Research Ltd. It sold out of 5: Indegene Ltd, Blue Jet Healthcare Ltd, Pfizer Ltd, Eris Lifesciences Ltd, Jubilant Pharmova Ltd. It added shares in 43.
Through Mirae Asset Mutual Fund's website or app, a mutual fund distributor, or an investment platform. Choose the Direct plan to pay no distributor commission, or the Regular plan to invest through a distributor. The first investment is at least On exchange in multiple of 1 unit. With AMC: In multiples of 5,000 units. You can invest once or through a monthly SIP.
Ekta Gala, amp, Ritesh Patel.
NIL
Sources: NAV and expense ratio from AMFI. Holdings from the fund house's monthly portfolio statement. Fund facts from its scheme summary document, as on 16-10-2026.
This page is information, not investment advice. Mutual fund investments are subject to market risks; read all scheme related documents carefully. Past returns do not promise future returns. Figures come from AMFI, NSE, BSE and each fund house's own documents.
Track Mirae Asset Nifty 500 Healthcare ETF in WealthGamma
Add this fund once. WealthGamma updates its value every day and shows it next to your stocks, gold, deposits and loans.
PAN not required · No broker linking · No OTPs